Merck & Co. Inc. (MRK), known as MSD outside the U.S. and Canada, said hat the U.S. Food and Drug Administration has accepted for review a new Supplemental Biologics License Application or sBLA for Keytruda (pembrolizumab), the company's anti-PD-1 therapy, to include data from KEYNOTE-010.
from RTT - Biotech http://ift.tt/1StTfTE
via IFTTT
No comments:
Post a Comment